Af­ter re­cruit­ing an As­traZeneca vet as CEO to head a new team and rais­ing $139M cash, lit­tle Ole­ma ap­pears to be ready to launch … some­thing

Sean Bo­hen is man­ag­ing his re-en­try in­to the R&D world in style. And he’s swerv­ing straight in­to the fast lane.

A cou­ple of weeks af­ter we chat­ted about the end of his sab­bat­i­cal fol­low­ing his de­par­ture from As­traZeneca as CMO and his new job as CEO of Ole­ma On­col­o­gy, Bo­hen took the wraps off of an $85 mil­lion in­vest­ment round that puts him in league with some of the high­est pro­file in­vestors in the field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER